Difference between revisions of "Paliperidone ER-Lurasidone"
From Psychiatrienet
| Line 6: | Line 6: | ||
| stop = {{Lastinjection}} | | stop = {{Lastinjection}} | ||
| start = {{StartOral afterDepot} | | start = {{StartOral afterDepot} | ||
| − | | info = {{RefSwitchToLurasidone}} | + | | info = |
| + | {{RefSwitchToLurasidone}} | ||
* the T<sub>1/2</sub> of a monthly paliperidon depot is approximately '''25-49 days'''.<ref> KNMP Kennisbank, informatorium medicamentorum: Olanzapine</ref> | * the T<sub>1/2</sub> of a monthly paliperidon depot is approximately '''25-49 days'''.<ref> KNMP Kennisbank, informatorium medicamentorum: Olanzapine</ref> | ||
}} | }} | ||
Revision as of 14:10, 20 February 2025
* This switch is intended for paliperidone long acting (Xeplion®, 30 days)
{{Drugswitch | from = Paliperidone LA | to = Lurasidone[1] | stop =
- Day 1: Last depot injection
| start = {{StartOral afterDepot} | info =
- More information on switching to lurasidon: see reference. [2]
- the T1/2 of a monthly paliperidon depot is approximately 25-49 days.[3]
}}
- ↑ A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2
- ↑ McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.
- ↑ KNMP Kennisbank, informatorium medicamentorum: Olanzapine
